Experience

• 

  Aspen Pharma

  • China

  • General Manager of Aspen Nutritionals

    • Jul 2016 - Oct 2017
    • China

    Aspen Pharma is a public-listed leading global pharmaceuticals player in specialty, branded and generic pharmaceuticals; and, which is based in South Africa with a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential.Aspen has a strong presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. The Group supplies medicines, products and infant formulae to more than 150 countries.My responsibility was to launch a new series of alula infant formulae, alula, in China.

• 

  Daiichi Sankyo, Inc.

  • Shanghai City, China

  • General Manager, Sales & Marketing Division

    • Mar 2015 - Jan 2016
    • Shanghai City, China

    FOUR business units namely, M&S Supporting Unit, Cardiovascular, Anti-Infectives & Urology, Respiratory & Analgesic, are reporting to the General Manager of Sales & Marketing Division. There is a team of >1,000 people covering functions of sales, marketing, commercial, market access, salesforce effectiveness, key account and training.The products promoting by the team are Olmetec (ARB), Mevalotin (Statin), Cravit (Quinolone), Urief (α1-blocker), Carbenin (Carbapenems), Asmeton (Cough Preparation) and Loxonin (NSAID) with a revenue of ~2 billion CNY and growth rate of 23%.

• 

  DKSH

  • Shanghai

  • General Manager - Rx & OTC, DKSH (Shanghai) Ltd.,

    • Feb 2012 - Feb 2015
    • Shanghai

    The General Manager is fully accountable for the profitable growth and development of the business line Pharma in the China marketplace. The incumbent is expected to develop, communicate and execute a compelling vision for the business aligned with the Global HEC BU and China business strategy. The General Manager will drive the business with focus on building a profitable and sustainable business, build the organisation, managers and key staff, lead business development by bringing in new brands and business partners and suppliers and grow the brands in the most efficient way.1. Created and drove the culture of marketing-driven, evidence-based management and coaching;2. Turned around the business unit into a profitable cost center with a sales growth rate of 23% compared to 13% market growth;3. Revitalized Levitra market after abandoned by Bayer from 1% to 14% market share in hospital market and 0.5% to 6% in OTC market in 2 years;4.Leading the defined market of Hirudoid by focus on dermatology segment with a strong growth of market share from 43% (2012) to 51 % (2013);5. Licensed in Tamiflu & Dormicum from Roche and Mobic from Boehringer Ingelheim. These two products became a significant profit contributors to DKSH;6. Changed the market environment of Tamiflu from a strategic stock product to a sustainable and prescribable drug for flu (H7N9);7. Built-up the DKSH Marketing Academy which was adapted in Asia Pacific8. Road model of Sales Force Effectiveness in Asia Pacific

• 

  Freelancer

  • Shanghai

  • Master Facilitator

    • Mar 2011 - Feb 2012
    • Shanghai

    - works as a Freelance Facilitator on marketing, sales management, leadership and business acumen programs for BTS, IMS and BizPro- developed and delivered marketing workshop and programs for Roche, Bayer and DKSH

• 

  BTS

  • China

  • Managing Director

    • Oct 2009 - Sep 2011
    • China

    Douglas has joined BTS China since Oct 2009 and started to do the company registration and building up the office in ShanghaiDouglas leading the China team by exceeding the new local business target by 40% besides the global business and started to generate profit in the 1st year operationDouglas won the largest training contract in Asia Pacific and which is one of the most comprehensive marketing simulation program in BTS. Douglas helped sanofi-aventis China to formulate and build up their marketing academy from scratch. The programs included Strategic Marketing, Tactical Marketing and Know Your Customer (Hospital Board) by applying the most advanced learning methodology, i.e. business acumen, IT-simulation, engage maps and the “Advantage Way”.Douglas was appointed by Bayer as the preferred facilitator of Fundamental of Marketing.Douglas rolled-out the GSK Leadership Program in China.Douglas explored and engaged in local banking industry, i.e. Agricultural Bank of China, Bank of China and People’s Bank of China.

• 

  IMS Market Research Consulting (Shanghai) Co. Ltd.

  • Principal

    • Feb 2007 - Oct 2009

    Douglas has joined IMS China since Feb 2007 and he has strongly demonstrated his capability and enthusiasm in consistently establishing and growing LSCM business in China. With his full dedication, he has been motivating and leading the account team to win five major LSCM in-house programs respectively from Pfizer, MSD, Novartis, Roche and Novo Nordisk with significant revenue contribution which doubled 2007 sales and exceeded 2007 sales target by 20% with a growth of 84% versus 2006Douglas has successfully delivered all the LSCM open and in-house programs and has ensured great success and excellent customer feedback. He achieved with an average rating of 6.32 out of 7 of the overall impression of instructor. Douglas and his supporting team won 2 Perfect Score of Client Satisfaction surveys for LSCM from Sanofi-Pasteur and Pfizer, respectivelyDouglas was playing a leading role to make a great team contribution to the IMS LSCM offer by customizing Segmentation & Targeting and Area Planning & Management programs to the vaccine and consumer health business. And, he built a training program from scratch “Quantitative SWOT Analysis Tool” and a stack of 74 slides of power point which has been extremely well received by the client and will constitute a great driver for growth in APAC and the rest of the globeDouglas developed a series of marketing tools, i.e. micro-marketing tools, 20-80 principle tools, buying process tools and potential indicators tools, etc for concept building and training purposeDouglas won the Asia Pacific Brand Recognition Award and was nominated to the Global Excellence Award in 2007

• 

  Daiichi Sankyo China

  • Marketing Director

    • May 2003 - Nov 2006

    1. Management of 2 Marketing Vice-Director, 5 Product Managers, 5 Promotion Managers, 2 Training Managers, 1 Market Development Manager, 1 Medical Affairs Manager and 3 Marketing Associates2. Management of Anti-infective and Chemotherapy Business Unit with 1 National Sales Manager, 5 District Sales Managers and 23 Medical Representatives3. Product management of Mevalotin (statin for dyslipidemia), Loxonin (NSAID for pain relief), Asmeton (-stimulant combo for asthma and cough), Banan (3rd generation oral cephalosporin for bacteria infection), Nidran (anti-brain cancer) and Benicar (angiotensin II receptor blocker for hypertension)4. KOL development in cardiology, endocrinology, nephrology, orthopaedic, rheumatology, neurology, gerontology, anti-infectives, respiratory and oncology 5. Enforce salespersons training and formulate coaching and counseling system for sales management6. Established the second version of Sales Information System (SIS) included SalesForce Effectiveness (SFE) and Customer Relationship Management (CRM)7. Involve in new products registration included Benicar [olmesartan] – ARB for hypertension, Kremezin [spherical adsorptive carbon] – for renal failure and their pre-launch activities

• 

  Merck Sharp & Dohme (China) Limited

  • Group Product Manager

    • Aug 1999 - Jan 2003

    1. Management of 3 Product Managers, 3 Marketing Associates and 5 Promotion Managers.2. Product range: cardiovascular products, i.e. Zocor, Cozaar, Hyzaar and Aggrastat.3. Formulate Heart Care Network (HCN) that is a hospital program with patient education. Working with 12 HCN specialists who report to sales.4. Work with Marketing Service to manage a patient database of 77,000.5. Community patient education program in Shanghai and Beijing.6. KOL development in cardiology, endocrinology and neurology.7. Turnover: >30M that contribute to one third of the total company sales.ACHIEVEMENT1. Zocor lead the lipid-lowering market with a strong growth rate at 76% in the past 2 years.2. Cozaar / Hyzaar grew by 217% from 1999 to 2001. Cozaar becomes the No. 4 branded antihypertensive agent in China by the end of Q1, 2002.3. Switch Zocor 5 mg to 20 mg within 6 months and successfully changed doctor perception on prescribing Zocor higher dose.

• 

  Baker Norton

  • Marketing Manager

    • Feb 1999 - Jul 1999

• 

  Pharmacia & Upjohn

  • Senior Product Manager – Anti-infectives

    • Dec 1996 - Aug 1998

• 

  Eli Lilly

  • United States
  • Pharmaceutical Manufacturing
  • 700 & Above Employee

  • Regional Sales Manager

    • Oct 1995 - Dec 1996

  • Product Manager

    • Jun 1994 - Sep 1995

• 

  Sandoz

  • Marketing Associate

    • Nov 1993 - May 1994

• 

  Edward Keller

  • China

  • Food Specialist

    • Dec 1989 - Sep 1990
    • China

    Being the First Representative launched Frisolac and Frisomil in China

• 

  Wyeth

  • China

  • China Trade Executive

    • May 1987 - Dec 1989
    • China

    Being the first representative launched S26 infant formulae series in China

• 

  GlaxoSmithKline

  • Sales Supervisor

    • Oct 1983 - May 1987